Organisation paid for research Program year 2025 Source: CMS Open Payments

Arizona Oncology

Neither a doctor nor a teaching hospital

Research payments

$2,682,873

398 payments

Through program year 2025, Arizona Oncology is reported as receiving $2,682,873 in research payments, across 398 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $118,026 5
2024 Research $193,114 10
2023 Research $611,623 29
2022 Research $187,394 12
2021 Research $560,107 60
2020 Research $524,098 255
2019 Research $488,512 27

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,333,611 59 payments
  2. Genentech, Inc. $714,353 45 payments
  3. Astellas Pharma Global Development $349,765 29 payments
  4. Janssen Research & Development, LLC $116,363 233 payments
  5. GlaxoSmithKline, LLC. $88,823 15 payments
  6. Celgene Corporation $45,367 3 payments
  7. AbbVie, Inc. $16,800 3 payments
  8. Seattle Genetics, Inc. $12,474 5 payments
  9. Pharmacyclics LLC, An AbbVie Company $2,742 5 payments
  10. AstraZeneca UK Limited $2,574 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase III Multicenter Randomized Placebo Controlled Study of Atezolizumab Versus Placebo in Com $448,883 12 payments
  2. MAJIC A Phase III Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib plus Venetoclax versus Venetoclax plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma $298,751 2 payments
  3. An Open-Label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced Or Metastatic Malignant Solid Tumors (Ev-202) $292,543 26 payments
  4. A Retrospective Analysis of Biomarker Testing Variance and Treatment Patterns among Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network Community $214,541 21 payments
  5. A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer (CALLA) $190,122 6 payments
  6. A Phase III Randomized Multi Center Double Blind Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer (CALLA) $124,241 2 payments
  7. PH II Placebo Controlled of Mtig7192a and Atezo in Nsclc $88,407 4 payments
  8. a phase 3 prospective,multicenter,randomized,open label trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma $85,851 1 payment
  9. A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) $85,391 2 payments
  10. Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) $72,196 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record